Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor/ASA FDC Bioavailability Study
NCT07444164Phase 1Completed
- Sponsor
- Laboratorios Silanes
- Start
- Jan 2025
- Primary completion
- Jan 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ticagrelor and aspirin in acute coronary syndrome (ACS) and myocardial infarction (MI) (2 arms), sponsored by Laboratorios Silanes. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to t and 4 more. Started Jan 2025; status: completed.
02
Drugs
ticagreloraspirin
03
Conditions
acute coronary syndrome (ACS)myocardial infarction (MI)
Beyond the preview
Go deeper on NCT07444164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444164.